On Tuesday, Following U.S. Stocks were among the “Top Gainers”: Rigel Pharmaceuticals, (NASDAQ:RIGL), Parsley Energy, (NYSE:PE), Taubman Centers, (NYSE:TCO), Novavax, (NASDAQ:NVAX)

• Rigel Pharmaceuticals, (NASDAQ:RIGL), with shares inclined 3.08%, closed at $3.68.

• Parsley Energy, (NYSE:PE), with shares jumped 2.88%, settled at $14.31.

• Taubman Centers, (NYSE:TCO), with shares climbed 2.80%, and closed at $76.44.

• Novavax, (NASDAQ:NVAX), with shares climbed 2.62%, and closed at $9.02.

Latest NEWS regarding these Stocks are depicted underneath:

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Formerly on March 3, Rigel Pharmaceuticals, Inc. (RIGL), stated financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel stated a net loss of $22.3 million, or $0.25 per share, contrast to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.

Contract proceeds from collaborations of $8.3 million and $5.8 million in the fourth quarters of 2014 and 2013, respectively, were comprised of non-refundable payments earned from AstraZeneca AB (AZ) as a result of its continued development of R256 in asthma.

Rigel stated total costs and expenses of $30.6 million in the fourth quarter of 2014, contrast to $22.7 million in the fourth quarter of 2013. The raise in costs and expenses was primarily due to a charge related to the loss on executing a sublease during the quarter, in addition to an raise in stock-based compensation expense and severance costs related to the retirement of Rigel’s former chief executive officer, partially offset by the decrease in research and development costs. The loss on the sublease is determined based on the present value of the excess of Rigel’s future remaining payments to its landlord through January 2018 associated with the applicable subleased space over its contractual sublease revenue from its subtenant over the term of the sublease contract Rigel executed in December 2014. The research and development costs in the fourth quarter of 2013 were comprised of certain non-recurring development costs related to the transfer of fostamatinib raw materials from AZ. Research and development costs reduced in 2014 due to the completion of a Phase 2 clinical study with R348 in dry eye and the discontinuation of a Phase 1 clinical study with R118, Rigel’s indirect AMPK activator program.

For the year ended December 31, 2014, Rigel stated contract proceeds from collaborations of $8.3 million and a net loss of $90.9 million, or $1.04 per basic and diluted share, contrast to contract proceeds from collaborations of $7.2 million and a net loss of $89.0 million, or $1.02 per basic and diluted share, in 2013. Contract proceeds from collaborations in 2014 and 2013 comprised of $8.3 million and $5.8 million, respectively, of non-refundable payments earned from AZ, and a non-refundable payment of $1.4 million in 2013 from Daiichi Sankyo related to their investigational new drug application filing for an oncology compound.

Rigel Pharmaceuticals, Inc., a clinical-stage drug development corporation, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, in addition to muscle disorders.

Parsley Energy, Inc. (NYSE:PE)

Formerly on February 26, Parsley Energy, Inc. (PE), declared financial and operating results for the fourth quarter ended December 31, 2014.

Highlights:

• As formerly stated, net production averaged 18.2 MBoe/d, an raise of 19% over Q3 2014. Oil volumes raised 31% quarter-over-quarter, representing 57% of total production in Q4 2014.
• Full year 2014 production raised 184% over full year 2013 to 14.2 MBoe/d, with organic growth driving more than 90% of the raise.
• Parsley formerly issued 2015 production guidance of 18.0-19.0 MBoe/d, representing about 30% year-over-year growth at the midpoint on a formerly declared capital budget that is about 50% lower than the Corporation’s 2014 capital expenditures.
• As formerly declared, Parsley attained bolt-on assets in the heart of the Corporation’s horizontal development area for $139 million, comprising of about 8,450 net acres, primarily in Northwest Reagan County. During 2014, Parsley raised net acreage in its Core and Tier 1 operating areas by almost 60%.
• Proved reserves at year-end 2014 raised 66% to 90.9 MMBoe, while proved developed reserves raised 126% to 46.0 MMBoe from year-end 2013 reserves. Total reserves raised 36.1 MMBoe, replacing 694% of 2014 production volumes.
• The Corporation continues to drill and complete outstanding horizontal Wolfcamp B wells, with initial production rates among the best in the Midland Basin.
• Since the Corporation last published well results, Parsley accomplished four wells targeting the Wolfcamp B shale in Upton County. These wells had peak 30-day initial production (IP) rates per 1,000-foot lateral of 216 Boe/d on average.
• The two most recently accomplished Wolfcamp B wells with 30 days of production established Corporation records for scaled IP rates, averaging 240 Boe/d per 1,000-foot lateral.

Parsley Energy, Inc. is engaged in the attainment, development, production, exploration, and sale of crude oil and natural gas properties located primarily in the Permian Basin region of West Texas.

Taubman Centers, Inc. (NYSE:TCO)

Taubman Centers, Inc. (TCO), declared its Board of Directors has raised its share repurchase program by $250 million. This raise to the $200 million share repurchase program authorized in August of 2013 brings Taubman Centers’ total authorization to $450 million. The corporation plans to repurchase shares from time to time on the open market, or in privately negotiated transactions or otherwise, depending on market prices and other conditions.

Since this share repurchase program’s inception, the corporation has purchased 1,880,301 shares of its ordinary stock at an average price of $70.48 per share or $132.5 million. This comprises 1,093,230 ordinary shares purchased at an average price of $73.39 per share since the starting of 2015. If the remaining $317.5 million authorization is used at current market prices, the repurchase will represent just under seven percent of the corporation’s ordinary shares outstanding.

Purchases of ordinary stock will be financed with general corporate funds. Depending upon the amount of purchases and other factors, the corporation may also borrow funds under its lines of credit. There is no guarantee as to the number of shares to be purchased. This share repurchase plan may be modified, suspended or terminated without preceding notice.

Taubman Centers, Inc. operates as a real estate investment trust. As of June 30, 2005, the corporation owned a 63% managing general partner’s interest in The Taubman Realty Group Limited Partnership (the operating partnership).

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NVAX), a clinical-stage vaccine corporation focused on the discovery, development and commercialization of recombinant nano-particle vaccines and adjuvants, declared the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen’s efforts will be focused on the corporation’s lead product candidates, counting its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates.

Novavax, Inc., a clinical-stage vaccine corporation, focuses on discovering, developing, and commercializing recombinant nano-particle vaccines and adjuvants.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content described in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.